CINECA IRIS Institutional Research Information System

ROLANDO, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.285
EU - Europa 4.443
AS - Asia 2.266
SA - Sud America 49
AF - Africa 39
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 7
Totale 14.126
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.164
IT - Italia 1.209
CN - Cina 1.183
DE - Germania 579
IE - Irlanda 542
SE - Svezia 428
SG - Singapore 296
GB - Regno Unito 265
UA - Ucraina 260
FR - Francia 234
FI - Finlandia 215
PL - Polonia 164
KR - Corea 153
AT - Austria 149
DK - Danimarca 147
VN - Vietnam 146
CA - Canada 106
IN - India 103
JP - Giappone 99
ID - Indonesia 95
RU - Federazione Russa 45
TW - Taiwan 44
BE - Belgio 40
ES - Italia 37
HK - Hong Kong 36
AU - Australia 27
CH - Svizzera 27
TR - Turchia 27
BR - Brasile 25
NL - Olanda 23
GR - Grecia 22
EG - Egitto 14
MX - Messico 14
CZ - Repubblica Ceca 13
SN - Senegal 12
IR - Iran 11
JO - Giordania 10
NZ - Nuova Zelanda 10
UZ - Uzbekistan 10
AR - Argentina 9
SA - Arabia Saudita 8
TH - Thailandia 8
MY - Malesia 7
NO - Norvegia 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
EU - Europa 5
PT - Portogallo 5
RS - Serbia 5
AL - Albania 4
BG - Bulgaria 4
HU - Ungheria 4
IL - Israele 4
RO - Romania 4
CO - Colombia 3
IQ - Iraq 3
MO - Macao, regione amministrativa speciale della Cina 3
NG - Nigeria 3
PK - Pakistan 3
ZA - Sudafrica 3
AF - Afghanistan, Repubblica islamica di 2
BQ - ???statistics.table.value.countryCode.BQ??? 2
CY - Cipro 2
DZ - Algeria 2
EC - Ecuador 2
LT - Lituania 2
MD - Moldavia 2
MU - Mauritius 2
PH - Filippine 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
BZ - Belize 1
HR - Croazia 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
MW - Malawi 1
VE - Venezuela 1
Totale 14.126
Salva come PNG Salva come JPEG
Città #
Chandler 798
Ann Arbor 753
Fairfield 640
Dublin 538
Ashburn 506
Beijing 503
Torino 346
Woodbridge 333
Houston 328
Seattle 263
Wilmington 245
Singapore 210
Cambridge 207
Frankfurt am Main 177
Jacksonville 175
Pisa 172
Nyköping 166
Dearborn 165
Warsaw 155
Vienna 144
Medford 126
Princeton 122
Redwood City 121
Turin 120
Villeurbanne 114
Los Angeles 111
Dong Ket 109
Jakarta 91
Hangzhou 64
Fremont 60
Shanghai 60
Guangzhou 54
Milan 53
Munich 53
Boston 51
Helsinki 50
Boardman 49
Nanjing 43
Santa Clara 41
Taipei 40
New York 39
Brussels 38
San Diego 37
Washington 32
Ottawa 31
Toronto 30
Tokyo 27
Shenyang 24
Zhengzhou 24
Copenhagen 22
Jinan 22
Rome 22
Siena 20
Verona 20
Norwalk 19
Wuhan 19
Leinì 18
Xian 18
Hefei 17
Naples 17
Phoenix 16
Paris 15
Chengdu 14
Kunming 14
Seongnam 14
Upper Marlboro 14
Changsha 13
Nanchang 13
Nottingham 13
Hebei 12
Lansing 12
Seoul 12
Falls Church 11
London 11
Tianjin 11
Buffalo 10
Central 10
Lachine 10
Nuremberg 10
Silver Spring 10
West Jordan 10
Bari 9
Catania 9
Central District 9
Changchun 9
Florence 9
Toledo 9
Alessandria 8
Bologna 8
Cairo 8
Lappeenranta 8
Mountain View 8
Nürnberg 8
Pune 8
Tappahannock 8
Vancouver 8
Dallas 7
Delhi 7
Fuzhou 7
Granada 7
Totale 9.261
Salva come PNG Salva come JPEG
Nome #
Quinone based nitric oxide donating compounds 525
1,2,5-Oxadiazole analogues of leflunomide and related compounds 436
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance 406
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition 349
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance 287
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 283
New furoxan derivatives for the treatment of ocular hypertension 275
Doxorubicin-antioxidant multitarget drugs 266
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors. 265
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. 263
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease 256
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins 256
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 251
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity 227
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells 219
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile 214
Edaravone derivatives containing NO-donor functions 210
A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery 201
4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues 194
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins 191
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs 171
Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells 171
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells 169
New nitric oxide or hydrogen sulfide releasing aspirins 165
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria 161
A Nonmetal-Containing Nitric Oxide Donor Activated with Single-Photon Green Light 158
Anti-pseudomonas activity of 3-nitro-4-phenylfuroxan 147
Curcumin-loaded solid lipid nanoparticles bypass p-glycoprotein mediated doxorubicin resistance in triple negative breast cancer cells 144
Nitrooxymethyl Substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization 143
Nitrooxymethyl-Substituted Analogues of Rofecoxib: Synthesis and Pharmacological Characterization 139
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 139
gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension 135
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties 132
A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells 130
Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans 129
Searching for new NO-donor Aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid 127
A new class of NO-donor H3-Antagonists 126
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) 126
Water-Soluble Nitric-Oxide-Releasing Acetylsalicylic Acid (ASA) Prodrugs 126
Amphiphilic NO-Donor Antioxidants 123
Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells 123
Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae 122
Multitarget Drugs: Focus on the NO-donor hybrid drugs 119
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents 118
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity 118
Novel Antioxidant Agents Deriving From Molecular Combination of Vitamin C and NO-donor moieties 117
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 117
NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization 117
New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni 113
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 113
4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric γ-aminobutyric acid receptor binding site 111
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 110
A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light 110
Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells 109
Carnosine analogues containing Phenol substructures 108
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 108
Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug 108
Aceclofenac-galactose conjugate: design, synthesis, characterization and pharmacological and toxicological evaluations 106
Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor 101
Mitochondrial delivery of phenol substructure triggers mitochondrial depolarization and apoptosis of cancer cells 98
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma 96
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives 95
Hyperglycemia Promotes Chemoresistance Through the Reduction of the Mitochondrial DNA Damage, the Bax/Bcl-2 and Bax/Bcl-XL Ratio, and the Cells in Sub-G1 Phase Due to Antitumoral Drugs Induced-Cytotoxicity in Human Colon Adenocarcinoma Cells. 95
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents 93
DNA-targeted NO release photoregulated by green light 90
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 90
EFFICIENTLY TARGETING DRUG EFFLUX THROUGH MODULATION OF P-GLYCOPROTEIN ACTIVITY BY SMALL MOLECULES: DESIGN, BIOLOGICAL AND COMPUTATIONAL STUDY. 89
Identification of 2,3-diaminophenazine and of o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan 85
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 83
New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands 83
Searching for Balanced Hybrid NO-Donor 1,4-Dihydropyridines with Basic Properties 82
NO-Donor Furoxans Containing a Sulphonamide Moiety and Related Furazans as Potent Carbonic Anhydrase Inhibitors 81
Identification of 2,3-diaminophenazine and o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan 80
Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance. 80
Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin. 80
NO-donor Carnosine Derivatives As Potential Neuroprotective Agents 76
One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells 76
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells 74
PREPARATION AND CHARACTERIZATION OF LIPOSOMES CONTAINING A NEW ANTHRACYCLINE DERIVATIVE 72
No-donor phenols: a study of their antioxidant activity 71
NITRIC OXIDE DONOR DOXORUBICINS: A USEFUL STRATEGY TO ADDRESS THE PROBLEM OF MDR IN CANCER THERAPY 71
Multitarget Drugs: No-Donor Doxorubicins 69
Five-Membered N-Heterocyclic Scaffolds as Novel Amino Bioisosteres at γ-Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters 68
Physicochemical profiling of Sartans: detailed study of ionisation constants and distribution coefficients 68
NO-DONOR 1,4-DIHYDROPYRIDINE ANALOGUES OF AMLODIPINE 66
Novel amphiphilic nitric oxide releasing antioxidants: NMR spectroscopic study of their interaction with biomembrane models 65
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER 59
Novel NO-donor Doxorubicins 58
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE 58
Furoxan nitric oxide donors disperse Pseudomonas aeruginosa biofilms, accelerate growth, and repress pyoverdine production 58
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 58
New class of NO-donor soluble aspirins 57
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 57
Unsymmetrically Substituted Furoxans. Part 19. Methyl and Phenylfuroxansulfonic Acids and Related Sulfonamides 56
NOVEL SEMISYNTHETIC DOXORUBICINS WITH REDUCED CARDIOTOXICITY 56
Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols 53
Synthesis of NO-Donor Bisphosphonates and Their in Vitro Action on Bone Resorption 52
Multitarget drugs: NO-donor doxorubicins 52
Vasodilating profile of a new series of analogues of GTN 51
Preparation and characterization of liposomes containing a new anthracycline derivative. 51
Totale 13.535
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.334
article - articoli 0
book - libri 0
conference - conferenze 6.988
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.212 0 0 130 288 167 282 238 181 272 281 196 177
2020/20211.741 126 135 109 108 150 106 121 137 216 153 128 252
2021/20222.178 117 119 162 215 118 82 147 134 80 165 493 346
2022/20232.486 234 255 75 228 207 594 264 153 225 80 91 80
2023/20241.734 153 205 114 104 144 251 179 100 31 122 141 190
2024/2025452 68 208 176 0 0 0 0 0 0 0 0 0
Totale 14.572